Spectranetics Outlines Growth Opportunities at Analyst &

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Spectranetics Outlines Growth Opportunities at Analyst & Investor Meeting

COLORADO SPRINGS, Colo., Dec. 4, 2014 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (Nasdaq: SPNC ) will provide an overview of several transformative growth drivers within its Vascular Intervention and Lead Management businesses during its Analyst & Investor meeting today in New York City. The company is also providing its financial outlook for 2015.

"I am proud of our recent accomplishments, which put us in an excellent position to capitalize on some of the most exciting growth opportunities in the markets we serve. We achieved the in-stent restenosis indication, acquired an innovative product platform with AngioScore, for the first time entered the market for mechanical lead management tools and announced the pending acquisition of the Stellarex drug coated balloon platform from Covidien LP," said Scott Drake, President and CEO of Spectranetics. "These milestone achievements will drive accelerating revenue growth in 2015 and position us for meaningful operating leverage over time."

During the meeting, the Spectranetics management team will outline its plans to address the in-stent restenosis (ISR) opportunity, which is an estimated $350 million market in the United States. Spectranetics is targeting approximately $15 to $20 million of ISR-related revenue in 2015 and market share of at least 20% in approximately three years. Spectranetics will also be discussing the pending Stellarex™ acquisition, which expands the company's Vascular Intervention portfolio of solutions into the projected $700 million to $1 billion drug coated balloon segment. In Lead Management, several initiatives are underway to further develop the lead management segment, including infection awareness, global launch of the recently introduced mechanical lead extraction tools, and other programs targeted at unlocking this $700 million market opportunity.

2015 Outlook

Spectranetics' management will present the company's financial guidance for 2015 at the meeting. Because the Stellarex acquisition has not yet closed, its financial impact is excluded from guidance. The transaction is expected to close in early 2015.

Revenue is projected to be in the range of $258 million to $265 million, an increase of 28% to 30% over the company's 2014 outlook of $202.0 million to $203.5 million. The 2015 projected revenue includes reduced revenue in the range of $1.5 million to $2.0 million, or approximately 1%, due to the declining exchange rate of euros in relation to U.S. dollars.

  • Vascular Intervention revenue growth is anticipated to be in the range of 41% to 46%. This includes AngioSculpt revenue of $62 million to $66 million and ISR revenue of approximately $15 million to $20 million.
  • Lead Management revenue growth is estimated in the range of 11% to 12%.

Net loss, Non-GAAP Net loss and Adjusted EBITDA outlook all reflect improving trends compared with previously provided 2014 outlook. Net loss is projected to be in the range of $28.0 million to $32.0 million, or $0.66 to $0.75 per share. Non-GAAP net loss is projected to be in the range of $4.3 million to $8.3 million, or $0.10 to $0.20 per share. Adjusted EBITDA is anticipated to be in the range of $12.3 million to $16.3 million. Non-GAAP net loss and Adjusted EBITDA are non-GAAP financial measures. See "Reconciliation of non-GAAP Financial Measures" later in this release. Additional details supporting our 2015 outlook are provided below:

  • Gross margin is expected to increase by 50 to 100 basis points in 2015. Gross margin guidance for 2014 is 74.5% to 75%.
  • Research, development and other technology expenses are expected to be approximately 15.5% to 16.0% of revenue, an increase over 2014 guidance of 14.5%, based on continued product development and clinical trial investments.

Financial Impact of Stellarex™ acquisition to Spectranetics

As previously described, the financial impact of the pending Stellarex acquisition is not included in the company's 2015 Outlook. The acquisition of the Stellarex drug-coated balloon (DCB) platform is expected to close in early 2015.  

Consistent with previous disclosures, Spectranetics expects the acquisition of the Stellarex DCB platform will provide a revenue growth catalyst beginning in 2015, and has the potential to contribute at least $100 million of revenue within two to three years of commercialization in the United States. The investment required to capitalize on this opportunity will lead to estimated 2015 dilution of $28.0 million to $32.0 million, or $0.66 to $0.75 per share, driven primarily by research and development costs associated with the ongoing Stellarex clinical trial program. The company anticipates the transaction to be accretive to adjusted operating income, excluding special items, in the first full year following U.S. commercialization.

Webcast

All interested parties are invited to listen to the live webcast beginning at 8 a.m. (Eastern Standard Time) on December 4, 2014 at http://www.spectranetics.com . An archived presentation of the webcast will be available on the company's website for 30 days.

About Spectranetics

Spectranetics develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The company's products are sold in over 65 countries and are used to treat arterial blockages in the heart and legs and in the removal of pacemaker and defibrillator leads.

In June 2014, Spectranetics acquired AngioScore Inc., a leading developer, manufacturer and marketer of cardiovascular, specialty balloons.

The Company's Vascular Intervention (VI) products include a range of laser catheters for ablation of blockages in arteries above and below the knee as well as the AngioSculpt® scoring balloon used in both peripheral and coronary procedures. The Company also markets support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions. The company markets aspiration and cardiac laser catheters to treat blockages in the heart.

The Lead Management (LM) product line includes excimer laser sheaths, mechanical sheaths and accessories for the removal of pacemaker and defibrillator cardiac leads.

For more information, visit www.spectranetics.com .

About the Stellarex DCB Platform

The Stellarex DCB platform is designed to treat peripheral arterial disease. On November 2, 2014, the company announced it entered into a definitive agreement under which it will purchase the Stellarex DCB platform from Covidien LP. Stellarex uses EnduraCoat™ technology, a durable, uniform coating designed to prevent drug loss during transit and facilitate controlled, efficient drug delivery to the treatment site. The Stellarex DCB platform currently is not approved for sale in any market.

Safe Harbor Statement

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. You can identify these statements because they do not relate strictly to historical or current facts. Such statements may include words such as "anticipate," "will," "estimate," "expect," "look forward," "strive," "project," "intend," "should," "plan," "believe," "hope," "enable," "potential," and other words and terms of similar meaning in connection with any discussion of, among other things, future operating or financial performance, strategic initiatives and business strategies, clinical trials, regulatory or competitive environments, our intellectual property and product development. These forward-looking statements include, but are not limited to, statements regarding our expectation of continued growth and strength and the reasons for that growth, growth rates, strength, integration and product launches, and 2014, 2015 and further outlook including projected revenue, gross margin, research and development costs, net loss and Adjusted EBITDA. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements and to note they speak only as of the date of this release. These risks and uncertainties may include financial results differing from guidance, inability to successfully integrate AngioScore into our business, market acceptance of excimer laser atherectomy technology and our vascular intervention and lead removal products, increasing price and product competition, increased pressure on expense levels resulting from expanded sales, marketing, product development and clinical activities, uncertain success of our strategic direction, dependence on new product development, loss of key personnel, uncertain success of or delays in our clinical trials, adverse results in any ongoing legal proceeding, or any legal proceeding in which we may become involved, adverse impact to our business of the health care reform and related legislation or regulations, including changes in reimbursements, continued or worsening adverse conditions in the general domestic and global economic markets and continued volatility and disruption of the credit markets, which affects the ability of hospitals and other health care systems to obtain credit and may impede our access to capital, intellectual property claims of third parties, availability of inventory from suppliers, adverse outcome of FDA inspections, the receipt of FDA approval to market new products or applications and the timeliness of any approvals, market acceptance of new products or applications, product defects, ability to manufacture sufficient volumes to fulfill customer demand, availability of vendor-sourced components at reasonable prices, unexpected delays or costs associated with any planned improvements to our manufacturing processes, and share price volatility due to the initiation or cessation of coverage, or changes in ratings, by securities analysts. For a further list and description of such risks and uncertainties that could cause our actual results, performance or achievements to materially differ from any anticipated results, performance or achievements, please see our previously filed SEC reports, including those risks set forth in our 2013 Annual Report on Form 10-K and our Quarterly Report on Form 10-Q for the three months ended June 30, 2014. We disclaim any intention or obligation to update or revise any financial or other projections or other forward-looking statements, whether because of new information, future events or otherwise.

Use of Non-GAAP Financial Measures

To supplement our condensed consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures in this release. Reconciliations of the non-GAAP financial measures used in this release to the most directly comparable GAAP measures for the respective periods, and an explanation of our use of these non-GAAP measures, can be found in "Reconciliation of Non-GAAP Financial Measures" below. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for our financial results prepared in accordance with GAAP.

Reconciliation of Non-GAAP Financial Measures

To supplement our condensed consolidated financial statements prepared in accordance with GAAP, we use certain non-GAAP financial measures in this release. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP measures for the respective periods can be found in the tables below. An explanation of the manner in which our management uses these non-GAAP measures to conduct and evaluate our business and the reasons management believes these non-GAAP measures provide useful information to investors are provided following the reconciliation tables.

Reconciliation of 2015 Projected Net Loss to Non-GAAP Projected Net Loss
(in millions)
(unaudited)
     
  Projected Range
  Twelve Months Ending
  December 31,
2015
December 31,
2015
Net loss, GAAP  $ (32.0)  $ (28.0)
Acquisition-related integration costs (1) 7.0 7.0
Acquisition-related amortization & contingent consideration expense (2) 16.7 16.7
Non-GAAP net loss  $ (8.3)  $ (4.3)
     
     
Reconciliation of 2015 Projected Net Loss Per Share to Non-GAAP Projected Net Loss Per Share
(unaudited)
     
  Projected Range
  Twelve Months Ending
  December 31,
2015
December 31,
2015
Net loss per share, GAAP  $ (0.75)  $ (0.66)
Acquisition-related integration costs (1) 0.16 0.16
Acquisition-related amortization & contingent consideration expense (2) 0.39 0.39
Non-GAAP net loss per share (3)  $ (0.20)  $ (0.10)
     
THE SPECTRANETICS CORPORATION
Reconciliation of 2015 Projected Net Loss to Adjusted EBITDA
(in millions)
(unaudited)
  Projected Range
  Twelve Months Ending
  December 31,
2015
December 31,
2015
Net loss, GAAP  $ (32.0)  $ (28.0)
Income tax expense 1.0 1.0
Interest expense, net 7.0 7.0
Depreciation and amortization 12.6 12.6
Acquisition-related integration costs (1) 7.0 7.0
Acquisition-related amortization & contingent consideration expense (2) 16.7 16.7
Adjusted EBITDA  $ 12.3  $ 16.3
     
__________________    
     
1)  Acquisition-related integration costs are related to the AngioScore acquisition, which closed on June 30, 2014, and primarily include severance and retention costs of approximately $2.1 million. In addition, these costs include legal fees associated with a patent-related matter in which AngioScore is the plaintiff of approximately $4.9 million.
     
2)  Acquisition-related intangible asset amortization relates to intangible assets acquired in the AngioScore acquisition in June 2014 and intangible assets acquired from Upstream Peripheral Technologies Ltd. ("Upstream"), and amortization of acquired inventory step-up related to the inventory acquired in the AngioScore acquisition. Contingent consideration expense represents the accretion of the estimated contingent consideration liability related to future amounts payable to former AngioScore stockholders primarily based on sales of the AngioScore products and achievement of product development milestones, and to Upstream, primarily based on sales of the products acquired.
     
3)  Per share amounts may not add due to rounding.

Management uses the non-GAAP financial measures as supplemental measures to analyze the underlying trends in our business, assess the performance of our core operations, establish operational goals and forecasts that are used in allocating resources and evaluate our performance period over period on a comparable basis and in relation to our competitors' operating results. In general, the income or expenses that are excluded from non-GAAP financial measures are intended to enhance the comparability of results between periods and are non-cash costs or non-recurring costs.

We believe presenting the non-GAAP financial measures used in this release provides investors greater transparency to the information used by our management for financial and operational decision-making and allows investors to see our results "through the eyes" of management. We also believe providing this information better enables our investors to understand our operating performance and evaluate the methodology used by management to evaluate and measure such performance.

Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for our financial results prepared in accordance with GAAP. Some limitations associated with using these non-GAAP financial measures are provided below:

  • Management exercises judgment in determining which types of charges or other items should be excluded from the non-GAAP financial measures used.
     
  • Depreciation and amortization expense, while not requiring cash settlement, are ongoing and recurring expenses and have a material impact on GAAP net income and reflect costs to us not reflected in Adjusted EBITDA.
     
  • Items such as acquisition-related integration costs and contingent consideration expense excluded from Adjusted EBITDA and Non-GAAP Net Loss can have a material impact on cash flows and GAAP net income and reflect economic costs to us not reflected in Adjusted EBITDA.
     
  • Non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles and therefore other companies may calculate similarly titled non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes.

COMPANY CONTACT The Spectranetics Corporation Guy Childs, Chief Financial Officer (719) 633-8333 INVESTOR CONTACTS Westwicke Partners Lynn Pieper (415) 202-5678

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Makers Nutrition Credit Puts a Clock on New Brands

Updated Category News Views 163

A few cents per bottle can look downright beautiful when a new supplement brand is staring at its first production bill. Makers Nutrition announced on November 17 a Black Friday manufacturing-credit offer aimed at entrepreneurs and established sellers launching a new formulation, with qualifying new orders eligible for as much as $0.45 per unit through November 29, 2026....

Continue Reading
SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 89

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading
Elisity’s Texas Water Pilot Puts IonQ’s Deal in View

Updated Category News Views 129

Water-system security is not a place for chest-thumping Elisity’s role in Texas Project Watershed 250 lands on a problem that is painfully concrete: water and wastewater utilities have to keep pumps, treatment systems and plant operations running while trying to close cybersecurity gaps. That is a tougher job than selling another dashboard to a corporate IT department....

Continue Reading
Docusign Pushes Contract Data Into ChatGPT Sales Tools

Updated Category News Views 120

Contracts are where sales momentum goes to get lost, buried under old PDFs, approval chains, and somebody’s half-finished CRM note. Docusign’s November 17, 2026 launch is a sensible attempt to drag that information into the place sellers may increasingly spend their working day: ChatGPT for Sales. The company’s new plugin lets a sales rep pull agreement intelligence...

Continue Reading
Envision and Tai Tam Put 45 MW Wind Bet to Work in Vietnam

Updated Category News Views 25

A wind site averaging 6.5 meters per second can look unremarkable on a map, yet that is precisely where equipment choices start separating serious developers from brochure merchants. Envision Energy and Vietnam's Tai Tam Group are taking that test on with the 45 MW Phuoc Dan wind project in Khanh Hoa Province. The arrangement follows five years of cooperation, but the...

Continue Reading
DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 25

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading
TYYY Liquidation Leaves Holders With a Tight Exit Window

Updated Category News Views 144

A fund can vanish faster than investors can read the fine print, and TYYY is doing exactly that. Exchange Traded Concepts has approved the closure and liquidation of the xETFs TSLA Daily Income ETF, with the fund expected to cease operations and distribute cash on or about November 20, 2026. This is not a debate about whether holders should love or hate Tesla. The product...

Continue Reading
Iberostar's Grand Move: Opening in Zanzibar

Updated Category News Views 74

The Resort That Takes Your Breath Away Here we have Iberostar, boldly wading into the azure waters of the Indian Ocean, planting its flag on the sandy beaches of Zanzibar. This isn’t just another notch on the resort’s belt—it’s their first time setting up shop in East Africa, a move ripe with promise and adventure both. A Suite So Sweet 358 suites, mind you. Each...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 84

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
Bona's 2027 Floorcast Finds Wood and Trust Still Win

Updated Category News Views 147

Floors are turning into a long-game purchase again Gray flooring may be limping toward the exit, but the more important signal in Bona's 2027 Floorcast is that homeowners are thinking less like bargain hunters and more like custodians of an expensive asset. That is a useful read for anybody watching the home-improvement and maintenance landscape. People do not replace a...

Continue Reading

Top 5 Most Recently Viewed Articles

Joseph Margolis Shows Strong Faith in Extra Space Storage

Updated Category News Views 133

Joseph Margolis Shows Strong Faith in Extra Space Storage Recently, a significant insider purchase was conducted by Joseph Margolis, who holds the position of Chief Executive Officer at Extra Space Storage (EXR). According to the latest SEC filing, Margolis acquired 27,741 shares of the company, amounting to a considerable investment of $4,232,166. The market had a...

Continue Reading
Investigation Into Arcadium Lithium Sale Sparks Concerns

Updated Category News Views 192

Investigation Launched into Arcadium Lithium Shareholder Rights The former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., is leading an inquiry regarding an important corporate transaction involving Arcadium Lithium plc (NYSE: ALTM). This investigation, undertaken by the law firm Kahn Swick & Foti, LLC, seeks to assess whether the terms of the proposed sale to...

Continue Reading
Actian Introduces Advanced Federated Data Catalog for Businesses

Updated Category News Views 148

Actian Launches Innovative Federated Data Catalog Actian, the data and analytics division of HCLSoftware, is setting new standards in data management with the introduction of the Actian Zeenea Federated Data Catalog. This advanced platform simplifies data discovery, empowering users across enterprises to harness valuable data resources effectively. With the acquisition of...

Continue Reading
Oil-Dri Corporation Reports Impressive Second Quarter Growth

Updated Category News Views 123

Oil-Dri Corporation Achieves Significant Growth Oil-Dri Corporation of America (NYSE: ODC), a reputable name in the production and marketing of sorbent mineral products, has shared its impressive financial performance for the second quarter of fiscal 2025, marking substantial growth for the company. Financial Highlights of the Second Quarter During this reporting period,...

Continue Reading
Power Metallic: Drill Assays Fuel Growth Optimism at Lion

Updated Category News Views 34

Striking Copper: Panning Out or Fools' Gold? Well, here's a dose of copper digging straight from the heart of the Lion Zone with Power Metallic Mines (TSXV: PNPN, OTCBB: PNPNF) at the helm. Now, if copper's your game, the latest assay results might just tickle your fancy. We're talking hefty 13.30 meters at 3.98% CuEqRec in hole 26-115 and, get this, a juicy 5.26 meters...

Continue Reading